Scienture Holdings reports Q1 2026 revenue of $56K, up 449% YoY

Scienture Holdings reported Q1 2026 revenue increased to $56 thousand from $10 thousand in Q1 2025, with gross margin expanding to 95.6%, driven by Arbli product orders and secured $11 million in debt financing. The company's early commercialization progress and patent portfolio expansion for specialty pharmaceutical products demonstrate operational momentum in the small-cap pharma sector.